Project Grant R01HL172493
Award Date
9/2/24
Completion Date
5/31/28
Dollars Obligated
$2.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
This $1,546,880 federal Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pittsburgh focused on understanding the regulation of myofibroblasts, a key cell type involved in the development of pulmonary fibrosis. The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, how E-box transcription factors regulate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support the development of an automated frailty scoring system for lung transplantation candidates. The $1,790,599 award to the University of Pittsburgh will fund research to validate a "bio-geo-composition" concept as a biomarker for assessing lung transplant fitness. The goal is to create the "Pittsburgh Transplant...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $750,162 to The Children's Hospital of Philadelphia (CHOP) Research Institute to support research on the role of lymphatic function and T-regulatory cells in preventing post-lung transplant complications. The key objectives of this research project are to: 1) determine the mechanisms of lymphatic vascular function after lung...
This federal Project Grant award, valued at $156,665.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania. The award supports a research project titled "Mesenchymal Cell Plasticity and Signaling in Lung Regeneration", which aims to examine how specific mesenchymal cell lineages contribute to adaptive versus maladaptive lung regeneration after severe...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $880,735 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Washington. The grant, with a project period from Feb 1, 2025 to Nov 30, 2028, supports research to uncover the mechanisms by which cell lysis (loss of plasma membrane integrity) leads to the induction of type 2 immunity in the lung. The research aims to identify alveolar macrophages as a key source of leukotriene C4 (LTC4)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $742,810 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Virginia (UVA) to develop diagnostic and monitoring tools using hyperpolarized gas magnetic resonance imaging (HGMRI) to detect and manage acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, determine HGMRI responses before and after rejection...
This federal Project Grant award in the amount of $2,803,961 was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a multi-year research effort by Northwestern University to investigate the integrated mechanisms underlying primary graft dysfunction and chronic lung allograft dysfunction following lung transplantation. The research is structured across four interrelated projects that aim to: 1)...
This $683,564 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand how aberrant signaling in alveolar epithelial cells contributes to the development of pulmonary fibrosis. The award to The Trustees of the University of Pennsylvania will fund studies using complementary in vivo mouse models and an induced pluripotent stem cell-based human alveolar type 2 cell model to investigate how the integrated...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996.00 to the University of Southern California to investigate the role of the PDLIM2 protein in regulating alveolar macrophage function and its impact on lung innate immunity, inflammation, and disease pathogenesis. The research aims to elucidate how PDLIM2 modulates alveolar macrophage phagocytosis, immune response, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,564,220 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania to develop an imaging-compatible ex vivo lung perfusion (EVLP) system. The goal is to obtain structural, functional, and metabolic biomarkers that can be used to optimize EVLP parameters and assess the reconditioning of donor lungs with common defects, such as atelectasis, ventilator-induced...